ANP fragment adjuvant therapy to standard of care (SOC) diuretic treatment

• US 10,004,754 B2
• Filed: 03/13/2015
• Issued: 06/26/2018
• Est. Priority Date: 03/14/2014
• Status: Active Grant

• Current Assignee: Madeleine Pharmaceuticals Pty Ltd
• Original Assignee: Madeleine Pharmaceuticals Pty Ltd
• Inventors: Geimer, Thomas Robert
• Primary Examiner(s): HOWARD, ZACHARY C
• Application Number:
  US15/124,804
• Publication Number:
  US 20170020899A1
• Time in Patent Office: 1,201 Days
• Field of Search: None
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/197 the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid carnitine A61K31/205
• CPC Class Codes: A61K 31/341 not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• CPC Class Codes: A61K 31/585 containing lactone rings, e.g. oxandrolone, bufalin
• CPC Class Codes: A61K 31/635 having a heterocyclic ring, e.g. sulfadiazine
• CPC Class Codes: A61K 38/2221 Relaxins
• CPC Class Codes: A61K 38/2242 Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 9/08 Vasodilators for multiple indications
• CPC Class Codes: C07K 14/58 Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin

Abstract

A therapeutic method for treating and/or preventing diseases and medical conditions typically treated by administering diuretic agents (eg congestive heart failure). The method may comprise, for example, administering to a subject a diuretic agent in combination with vessel dilator (VSDL) or a variant or modified peptide thereof. The administration of the diuretic agent may be a component of a standard of care (SOC) treatment.

Claims

1. A method for treating and/or preventing cardio-renal syndrome (CRS) in a subject with a severely decreased estimated glomerular filtration rate (eGFR) in the range of 15-24 ml/min/1.73 m², comprising administering to the subject a diuretic agent in combination with vessel dilator (VSDL).

2. The method of claim 1, wherein the subject shows diuretic resistance or refractory diuretic responsiveness.

3. The method of claim 1, wherein the diuretic agent is a loop diuretic and/or potassium-sparing diuretic.

4. The method of claim 1, wherein the diuretic agent is furosemide, spironolactone or a combination thereof.

5. The method of claim 1, wherein the administration of the diuretic agent comprises standard of care (SOC) treatment for the cardio-renal syndrome.

6. The method of claim 1, wherein the diuretic agent is furosemide and the method comprises administering the furosemide and the VSDL in combination with an ACE inhibitor.

7. The method of claim 6, further comprising administering a vasodilator agent.

8. The method of claim 7, wherein the vasodilator agent is relaxin.

9. The method of claim 7, wherein the vasodilator agent is an angiotensin receptor blocker (ARB).

10. The method of claim 7, further comprising administering a neprilysin (NEP) inhibitor.

11. The method of claim 10, wherein the NEP inhibitor is sacubitril.

12. The method of claim 7, further comprising administering an agent selected from CXL-1427 or TRV027.

13. The method of claim 6, further comprising administering an adenosine A1 receptor antagonist.